Maintenance of weight loss or stability in subjects with obesity: a retrospective longitudinal analysis of a real-world population

2017 ◽  
Vol 33 (6) ◽  
pp. 1105-1110 ◽  
Author(s):  
Maral DerSarkissian ◽  
Rachel H. Bhak ◽  
Joanna Huang ◽  
Sarah Buchs ◽  
Francis Vekeman ◽  
...  
2018 ◽  
Vol 16 (7) ◽  
pp. 1073-1080.e1 ◽  
Author(s):  
Eric J. Vargas ◽  
Carl M. Pesta ◽  
Ahmad Bali ◽  
Eric Ibegbu ◽  
Fateh Bazerbachi ◽  
...  

2005 ◽  
Vol 94 (0) ◽  
pp. 53a-53
Author(s):  
J Holm ◽  
M Gamborg ◽  
S Gammeltoft ◽  
L Ward ◽  
B Heitmann ◽  
...  

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 742-P
Author(s):  
AHMED H. ELDIB ◽  
SHAHEEN TOMAH ◽  
ADHAM MOTTALIB ◽  
SAHAR ASHRAFZADEH ◽  
OSAMA HAMDY

2021 ◽  
Vol 10 (9) ◽  
pp. 1890
Author(s):  
Gabriele Pesarini ◽  
Gabriele Venturi ◽  
Domenico Tavella ◽  
Leonardo Gottin ◽  
Mattia Lunardi ◽  
...  

Background: The aim of this research is to describe the performance over time of transcatheter aortic valve implantations (TAVIs) in a high-volume center with a contemporary, real-world population. Methods: Patients referred for TAVIs at the University Hospital of Verona were prospectively enrolled. By cumulative sum failures analysis (CUSUM), procedural-control curves for standardized combined endpoints—as defined by the Valve Academic Research Consortium-2 (VARC-2)—were calculated and analyzed over time. Acceptable and unacceptable limits were derived from recent studies on TAVI in intermediate and low-risk patients to fit the higher required standards for current indications. Results: A total of 910 patients were included. Baseline risk scores significantly reduced over time. Complete procedural control was obtained after approximately 125 and 190 cases for device success and early safety standardized combined endpoints, respectively. High risk patients (STS ≥ 8) had poorer outcomes, especially in terms of VARC-2 clinical efficacy, and required a higher case load to maintain in-control and proficient procedures. Clinically relevant single endpoints were all influenced by operator’s experience as well. Conclusions: Quality-control analysis for contemporary TAVI interventions based on standardized endpoints suggests the need for relevant operator’s experience to achieve and maintain optimal clinical results, especially in higher-risk subjects.


Nutrients ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1804
Author(s):  
Elena Tragni ◽  
Luisella Vigna ◽  
Massimiliano Ruscica ◽  
Chiara Macchi ◽  
Manuela Casula ◽  
...  

Background: The prevention and treatment of obesity and its cardio-metabolic complications are relevant issues worldwide. Among lifestyle approaches, very low-calorie ketogenic diets (VLCKD) have been shown to lead to rapid initial weight loss, resulting in better long-term weight loss maintenance. As no information on VLCKD studies carried on in a real-world setting are available, we conducted this multi-centre study in a real-world setting, aiming at assessing the efficacy and the safety of a specific multiphasic VLCKD program in women with overweight or obesity. Methods: A multi-center, prospective, uncontrolled trial was conducted in 33 outpatient women (age range 27–60 y) with overweight or obesity (BMI: 30.9 ± 2.7 kg/m2; waist circumference: 96.0 ± 9.4 cm) who started a VLCKD dietary program (duration: 24 weeks), divided into four phases. The efficacy of VLCKD was assessed by evaluating anthropometric measures and cardiometabolic markers; liver and kidney function biomarkers were assessed as safety parameters. Results: The VLCKD program resulted in a significant decrease of body weight and BMI (−14.6%) and waist circumference (−12.4%). At the end of the protocol, 33.3% of the participants reached a normal weight and the subjects in the obesity range were reduced from 70% to 16.7%. HOMA-IR was markedly reduced from 3.17 ± 2.67 to 1.73 ± 1.23 already after phase 2 and was unchanged thereafter. Systolic blood pressure decreased after phase 1 (−3.5 mmHg) and remained unchanged until the end of the program. Total and LDL cholesterol and triglycerides were significantly reduced by VLCKD along with a significant HDL cholesterol increase. Liver, kidney and thyroid function markers did not change and remained within the reference range. Conclusions: The findings of a multi-center VLCKD program conducted in a real-world setting in a cohort of overweight/obese women indicate that it is safe and effective, as it results in a major improvement of cardiometabolic parameters, thus leading to benefits that span well beyond the mere body weight/adiposity reduction.


Author(s):  
Amisha Wallia ◽  
Matthew J. O’Brien ◽  
David T. Liss ◽  
Raymond H. Kang ◽  
Andrew J. Cooper ◽  
...  

2017 ◽  
Vol 23 (4) ◽  
pp. 446-452 ◽  
Author(s):  
Jie Meng ◽  
Roman Casciano ◽  
Yi-Chien Lee ◽  
Lee Stern ◽  
Dmitry Gultyaev ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document